Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

The mobile commerce platform developer priced its initial public offering at the top of its range, with JD.com set to exit in the flotation.

The Eli Lilly-backed antibody discovery platform developer's shares opened at more than three times their IPO price to net it a valuation topping $15bn.

The Alphabet-backed accommodation marketplace priced its initial public offering well above its range in the second huge flotation this week, to secure a $47bn valuation.

SoftBank Vision Fund is the largest investor in the food delivery service, which has priced an upsized initial public offering roughly doubling its valuation six months ago.

The underwriters have taken up the over-allotment option in BMS and Celgene-backed oncology drug developer Silverback's initial public offering.

The ByteDance-backed learning software and tutoring services provider priced its shares in the middle of their range as it went public in the US.

Celgene and Bristol-Myers Squibb have scored exits as the oncology drug developer priced an upsized offering above its range.

JD.com's medical products spinoff has gone public in Hong Kong's largest initial public offering this year, valuing it at close to $29bn.

Sistema invested $67.5m in the e-commerce platform developer alongside an upsized initial public offering in which it floated above its range.